LaNova Medicines has announced the initiation of a Phase 1 clinical trial in China for LM-299, a bispecific antibody (BsAb) targeting both PD-1 and VEGF, in patients with advanced solid tumors. This first-in-human trial follows promising preclinical results that demonstrated significant tumor growth inhibition and a well-tolerated safety profile in preclinical models.
LM-299 is designed to simultaneously block the PD-1/PD-L1 and VEGF/VEGFR signaling pathways, aiming to achieve a synergistic anti-tumor effect by combining tumor immunity with anti-angiogenesis. The bispecific antibody features a molecular design that links an anti-VEGF antibody to a C-terminal anti-PD-1 antibody, which LaNova believes ensures high expression, optimal druggability, and best-in-class potential.
Clinical Development and Financing
In addition to the Phase 1 trial in China, LaNova Medicines plans to initiate another Phase 1 clinical trial in the United States, with an Investigational New Drug (IND) application expected to be submitted in the second half of 2024. The company has also completed a $42 million Series C1 financing round, led by Sino Biopharmaceuticals, with participation from new and current investors. The proceeds from this financing will primarily support the clinical development of LaNova's pipeline, including LM-299, LM-302 (anti-CLDN 18.2 ADC), and LM-108 (anti-CCR8 mAb).
LaNova's Pipeline
LaNova Medicines has a diverse pipeline of drug candidates, including:
- LM-302 (anti-CLDN 18.2 ADC): Currently in a Phase III registrational clinical trial in China for gastric cancers. A US Phase II trial is expected to start in H2 2025.
- LM-108 (anti-CCR8 mAb): Ongoing Phase II clinical trials in China for multiple solid tumors. A US Phase II trial is expected to start in H2 2024.
Executive Commentary
Dr. Crystal Qin, LaNova's founder, chairwoman, and CEO, stated, "Since its establishment, LaNova has been dedicated to original innovation, with a focus on the tumor microenvironment and the development of tumor-specific targeted ADCs and immune-modulating biologics... Proceeds from this financing will allow us to expedite the development of our late-stage clinical programs, LM-302 and LM-108, moving us closer to market approval. We will also accelerate the clinical development of LM-299, which is currently in Phase 1 clinical trials with best-in-class potential."
